SEC Filing Summary: Savara Inc. (Form 8-K)
Business Context and Reporting Period
This Form 8-K, dated May 9, 2017, reports the completion of a business combination between Savara Inc. (formerly Mast Therapeutics) and Aravas Inc. (formerly Savara Inc.) on April 27, 2017. Aravas is a clinical-stage specialty pharmaceutical company focused on rare respiratory diseases, specifically cystic fibrosis (CF) and pulmonary alveolar proteinosis (PAP). The filing provides unaudited interim consolidated financial statements and Management's Discussion and Analysis (MD&A) for Aravas for the three-month period ended March 31, 2017, which was not included in Savara's prior 10-Q.
Key Financial Metrics (Aravas Inc.)
Period: Three months ended March 31, 2017
- Revenue: $0 (No product revenue to date).
- Net Loss: $4.974 million.
- Operating Expenses: $4.774 million (R&D: $2.948 million; G&A: $1.736 million).
- Cash and Cash Equivalents: $10.464 million as of March 31, 2017.
- Accumulated Deficit: $43.380 million as of March 31, 2017.
- Debt: Convertible promissory notes carrying value of $3.597 million; Put option derivative liability of $1.055 million.
- Cash Flow: Net cash used in operating activities was $2.844 million.
Material Changes vs. Prior Period
Compared to the three months ended March 31, 2016:
- Net Loss: Increased by $3.298 million (197%) to $4.974 million.
- R&D Expenses: Increased by $1.686 million (134%) to $2.948 million. This was primarily driven by $2.0 million in development costs associated with the acquisition of Serendex and the advancement of the Molgradex candidate.
- G&A Expenses: Increased by $1.391 million (403%) to $1.736 million, due to merger-related costs, legal/accounting expenditures, and increased administrative personnel.
- Other Expense: Increased by $0.452 million, driven by interest expense on bridge notes and fair value changes on promissory note put options.
Guidance, Outlook, and Recent Events
Merger Completion: On April 27, 2017, Aravas became a wholly-owned subsidiary of Savara. Aravas pre-existing equity holders own approximately 77% of the combined company, while Savara (formerly Mast) holders own approximately 23%.
Capital Resources and Financing:
- 2017 Notes: Subsequent to March 31, 2017, Aravas raised approximately $3.5 million under 2017 Convertible Promissory Notes, which automatically converted into Savara common stock upon the Merger.
- ATM Facility: On April 28, 2017, Savara entered into a Sales Agreement with H.C. Wainwright to sell up to $18.0 million of common stock via "at-the-market" offerings.
- Debt Facility: On April 28, 2017, Savara secured a $15 million debt facility with Silicon Valley Bank. $7.5 million was immediately available (subject to a $100 million market cap) to repay pre-merger debt and fund operations. An additional $7.5 million tranche is available upon achieving specific capital raise milestones.
Outlook: The company expects to incur significant additional expenses and increasing operating losses for the foreseeable future as it advances clinical trials for Molgradex (PAP) and AeroVanc (CF). Substantial additional capital will be required to fund operations.
Risks: The filing highlights risks related to the failure to raise capital, the uncertainty of clinical trial results, regulatory approval delays, and the potential dilution of existing shareholders through future equity issuances.
Investor Verification Checklist
- Verify the final accounting treatment of the Merger, as initial accounting was incomplete at the time of filing.
- Confirm the status of the $15 million Silicon Valley Bank facility and whether the $100 million market cap condition for the first tranche was met.
- Monitor the progress of clinical trials for Molgradex and AeroVanc, as these drive future R&D spend and potential revenue.
- Review the terms of the $18 million ATM facility and any subsequent sales of shares.
- Assess the impact of contingent consideration liabilities ($9.8 million) related to the Serendex acquisition on future cash flows.